Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 15;2014(10):CD007890.
doi: 10.1002/14651858.CD007890.pub3.

Beta-blockers for preventing stroke recurrence

Luiz Gustavo De Lima  1 , Humberto Saconato, Alvaro N Atallah, Edina M K da Silva
Affiliations

Beta-blockers for preventing stroke recurrence

Luiz Gustavo De Lima et al. Cochrane Database Syst Rev. .

Abstract

Background: Stroke affects 15 million people per year worldwide. Despite recent developments in acute stroke treatment, prevention remains very important. Stroke has a high rate of recurrence; therefore secondary prevention is also important. Many clinical approaches to control risk factors have been proposed. One of these approaches is the prescription of beta-blockers that have effects beyond the reduction of blood pressure, which can reduce the recurrence of stroke.

Objectives: To evaluate the efficacy of beta-blockers for preventing stroke recurrence and for reducing death and major vascular events in people with a previous stroke or transient ischaemic attack (TIA), and to determine their safety, particularly with regard to the development of diabetes mellitus.

Search methods: We searched the Cochrane Stroke Group Trials Register (May 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane Database of Systematic Reviews (CDSR) (The Cochrane Library 2014, Issue 5), the Database of Abstracts of Reviews of Effects (DARE) (May 2014), MEDLINE (1966 to May 2014), EMBASE (1980 to May 2014), and Latin American and Caribbean Health Sciences Literature (LILACS) (1982 to May 2014). We also searched ongoing trials registers and reference lists.

Selection criteria: Randomised controlled trials (RCTs) that included participants with previous stroke or TIA due to arterial thrombosis or embolism. The intervention was any beta-blocker versus control, or beta-blocker plus other treatment versus other treatment.

Data collection and analysis: Two review authors independently screened the trials identified, appraised quality, and extracted data.

Main results: We included two RCTs involving 2193 participants in the review. Both studies randomised participants to either beta-blocker (atenolol 5 mg) or placebo and were of a high methodological quality. We noted no statistical differences among the groups in risks of fatal and non-fatal stroke (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.76 to 1.18). For other outcomes analysed (major vascular events, death from all causes, death from cardiovascular causes) , we observed no significant differences between the groups. There were minor blood pressure reductions in the intervention group. Neither of the included studies reported the occurrence of diabetes among their outcomes or assessed quality of life. Adverse events were significantly more frequent in participants taking atenolol than in those given placebo, and were the most common reason given for discontinuing treatment (RR 1.85, 95% CI 1.45 to 2.35).

Authors' conclusions: To date, no available evidence supports the routine use of beta-blockers for secondary prevention after stroke or TIA. More studies with larger samples are needed.

PubMed Disclaimer

Conflict of interest statement

Luiz Gustavo De Lima: none known. Humberto Saconato: none known. Álvaro N Atallah: none known. Edina MK da Silva: none known.

Figures

1
1
Study flow diagram.
1.1
1.1. Analysis
Comparison 1 Atenolol 50 mg versus placebo, Outcome 1 Fatal and non‐fatal stroke recurrence.
1.2
1.2. Analysis
Comparison 1 Atenolol 50 mg versus placebo, Outcome 2 Major vascular events.
1.3
1.3. Analysis
Comparison 1 Atenolol 50 mg versus placebo, Outcome 3 Death from all causes.
1.4
1.4. Analysis
Comparison 1 Atenolol 50 mg versus placebo, Outcome 4 Death from cardiovascular causes.
1.5
1.5. Analysis
Comparison 1 Atenolol 50 mg versus placebo, Outcome 5 Withdraw due to adverse effect.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

DUTCH TIA TRIAL 1993 {published data only}
    1. The DUTCH TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993;24:543‐8. - PubMed
Eriksson 1995 {published data only}
    1. Eriksson S, Olofsson B, Wester P. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases 1995;5:21‐2.

References to studies excluded from this review

Azuma 1997 {published data only}
    1. Azuma T, Matsubara T, Nagai Y, Funauchi M, Fujimoto T, Saito T, et al. Effects of antihypertensive agents on circadian blood pressure in hypertensive patients with previous brain infarction. Journal of Human Hypertension 1997;11:637‐40. - PubMed
Black 2003 {published data only}
    1. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular End points (CONVINCE) trial. JAMA 2003;289:2073‐82. - PubMed
Coope 1986 {published data only}
    1. Coope J, Warrender TS. Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ 1986;293:1145‐51. - PMC - PubMed
Dahlöf 1991 {published data only}
    1. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP‐Hypertension). Lancet 1991;338:1281‐5. - PubMed
Dahlöf 2002 {published data only}
    1. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995‐1003. - PubMed
Dahlöf 2005 {published data only}
    1. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Blood Pressure Lowering Arm (ASCOT‐BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895‐906. - PubMed
Hansson 1999a {published data only}
    1. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin‐converting‐enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999;353:611‐6. - PubMed
Hansson 1999b {published data only}
    1. Hansson L, Lindholm LH, Ekborn T, Dahlöf B, Lanke J, Schersten B, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension‐2 study. Lancet 1999;354:1751‐6. - PubMed
Hansson 2000 {published data only}
    1. Hansson L, Hedner T, Lund‐Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomized trial of effects of calcium antagonists compared with diuretics and β‐blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359‐65. - PubMed
Kinnander 1987 {published data only}
    1. Kinnander G, Viitanen M, Asplund K. Beta‐adrenergic blockade after stroke: a preliminary closed cohort study. Stroke 1987;18:240‐3. - PubMed
MRC 1985 {published data only}
    1. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97‐104. - PMC - PubMed
MRC 1992 {published data only}
    1. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1982;304:405‐12. - PMC - PubMed
SHEP 1991 {published data only}
    1. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255‐64. - PubMed
Wilhelmsen 1987 {published data only}
    1. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta‐blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. Journal of Hypertension 1987;5:561‐72. - PubMed

Additional references

BPLTTC 2003
    1. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood‐pressure‐lowering regimens on major cardiovascular events: results of prospectively‐designed overviews of randomized trials. Lancet 2003;362:1527‐35. - PubMed
Chalmers 2003
    1. Chalmers J, Todd A, Chapman N, Beilin L, Davis S, Donnan G, et al. International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. Journal of Hypertension 2003;21:651‐63. - PubMed
Collins 1990
    1. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short‐term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827‐38. - PubMed
Coull 2004
    1. Coull AJ, Rothwell PM. Underestimation of the early risk of recurrent stroke ‐ evidence of the need for a standard definition. Stroke 2004;35:1925‐9. - PubMed
Dhakam 2006
    1. Dhakam Z, McEniery CM, Yasmin C, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. American Journal of Hypertension 2006;19(2):214‐9. - PubMed
Gueyffier 1997
    1. Gueyffier F, Boissel JP, Boutitie F, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997;12:2557‐62. - PubMed
Hankey 1998
    1. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, et al. Long‐term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998;29(12):2491‐500. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Julius 2004
    1. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022‐31. - PubMed
Lawes 2008
    1. Lawes CMM, Hoorn SV, Rodgers A. Global burden of blood‐pressure‐related disease, 2001. Lancet 2008;371:1513‐8. - PubMed
Lindholm 2005
    1. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta‐analysis. Lancet 2005;366:1545‐53. - PubMed
MacMahon 1990
    1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765‐74. - PubMed
Messerli 2008
    1. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta‐blockers and diuretics precludes their use for first‐line therapy in hypertension. Circulation 2008;117(20):2706‐15. - PubMed
PROGRESS 2001
    1. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358(9287):1033‐41. - PubMed
Rashid 2003
    1. Rashid P, Leonardi‐Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003;34:2741‐8. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Sacco 1997
    1. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, et al. American Heart Association Prevention Conference: IV: prevention and rehabilitation of stroke: risk factors. Stroke 1997;28:1507‐17. - PubMed
Sacco 2006
    1. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: cosponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:577‐617. - PubMed
Shah 2000
    1. Shah H, Gondek K. Aspirin plus extended‐release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost effectiveness analysis. Clinical Therapy 2000;22:363‐70. - PubMed
Smith 2001
    1. Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. American Heart Association/American College of Cardiology guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577‐9. - PubMed
Strong 2007
    1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurology 2007;6:182‐7. - PubMed
Wiysonge 2007
    1. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD002003.pub2] - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources